SK Biopharmaceuticals launches epilepsy drug in France

The company successfully moved into all 5 major European markets

SK Biopharm's Cenobamate
SK Biopharm's Cenobamate
Jae-Young Han 1
2022-12-09 11:28:23 jyhan@hankyung.com
Bio & Pharma

South Korean SK Biopharmaceuticals Co. said on Friday that its treatment of epilepsy "Cenobamate" has been approved for sale in France.

The company launched the same drug in 15 European countries, beginning with Germany in June this year. The local drug brand name is "Ontozry."

With the introduction to France, the company stressed that it has succeeded in entering all five major European markets, including Germany, Britain, Italy, Spain, and France. The size of these five countries' epilepsy market is estimated at $1.7 billion, accounting for 73% of the total in Europe.

An SK Biopharm official said, "We expect to be able to earn milestone revenues in relation to sales royalties and sales from our European partner Angelini Pharma through the expansion of sales in the continent."

Cenobamate is a treatment for partial-onset seizures in adult patients with epilepsy.

Write to Jae-Young Han at jyhan@hankyung.com
#SK Biopharm #Cenobamate #Ontozry #epilepsy #Angelini Pharma

SK Biopharma's epilepsy treatment posts impressive growth in US

SK Biopharma's epilepsy treatment posts impressive growth in US

SK Biopharm researchers South Korean SK Biopharmaceuticals' epilepsy treatment Cenobamate has seen rapid growth on the US market.The company on Thursday said the medication's sales in the first three quarters hit 119.4 billion won ($89 million), with the third quarter alone seeing growth o

SK Biopharmaceuticals to make CES debut in January

SK Biopharmaceuticals to make CES debut in January

The researchers of SK Biopharmaceuticals (The courtesy of SK Biopharmaceuticals) SK Biopharmaceuticals will take part in CES 2023, the world's largest trade show for IT and electronics held in Las Vegas, to unveil its medical device for detecting signs of an epileptic seizure.The company will b

SK Biopharmaceuticals signs epilepsy drug deal with Brazil’s Eurofarma

SK Biopharmaceuticals signs epilepsy drug deal with Brazil’s Eurofarma

SK Biopharm researchers South Korea’s SK Biopharmaceuticals Co. has signed a deal to license out its technology for Cenobamate, an antiepileptic drug, to Brazil’s Eurofarma Laboratórios S.A. to enter the Latin American market.With the technology transfer, SK aims to sell

SK Biopharm releases epilepsy treatment in UK

SK Biopharm releases epilepsy treatment in UK

SK Biopharm's Cenobamate, sold under the Xcopri brand in the US South Korean SK Biopharmaceuticals Co. launched its epilepsy treatment Cenobamate in the UK, rapidly expanding the company’s presence in Europe.The UK is the fourth country in Europe for SK to sell the drug, which is availabl
(* comment hide *}